Skip to main content

Volume 6 Supplement 3

AIDS Vaccine 2009

P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02)

Background

The use of inactivated autologous HIV-1 from infected patients as an antigen formulation for a therapeutic vaccine involves the isolation and propagation of HIV in cell-culture conditions fulfilling the clinical grade Good Manufacturing Practice (GMP), and the development of analysis systems to detect adventitious agents. In this study we present the development of heat inactivated autologous HIV-1 produced Ex vivo to be used as immunogen in human therapeutic vaccine (Clinical Trial DCV02).

Methods

Autologous HIV-1 was isolated from 14 infected subjects (4.2 log HIV-1 cp RNA/mL plasma), by co-culture of the CD4-enriched PBMCs from these infected patients with CD4-enriched PBMCs pre-activated from healthy donors, during 21 days in X-Vivo 20 media, 10% of AB human serum and IL-2. Cell-culture supernatants were concentrated by ultrafiltration. Viral productions were analyzed by ELISA p24Ag-HIV-1 and RNA cp/mL in the final product. Adventitious agents were analyzed by cell culture in PBMCs, MRC-5 and VERO cell lines, microbiology cultures, gram and mycoplasma tests. The HIV-1 protease (PR) sequence was also analyzed.

Results

To obtain de immunogen from 14 patients it was necessary to perform 21 cell-cultures to produce the immunogen in optimal cGMP conditions. From each patient, a median of 80 mL of cell culture supernatant with a median of 8,8 log HIV-1 cp RNA/mL were heat inactivated and concentrated until a volume of 1 mL of final product with 9.8 log HIV-1 cp RNA/mL. No differences were found between HIV-1 PR sequences of cell culture and plasma. Heat inactivation reached an infectivity reduction median of 5.5 Log in 11 days PBMCs cell cultures.

Conclusion

Ex vivo isolation and production of autologous HIV-1 by cell co-culture fulfilling clinical grade GMP for therapeutic vaccine is feasible, but requires a concerted effort to guarantee the quality and safety of the final product.

Author information

Affiliations

Authors

Corresponding author

Correspondence to C Gil.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Gil, C., Climent, N., Hurtado, C. et al. P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02). Retrovirology 6, P316 (2009). https://doi.org/10.1186/1742-4690-6-S3-P316

Download citation

Keywords

  • VERO Cell
  • Good Manufacture Practice
  • Clinical Grade
  • Therapeutic Vaccine
  • Infected Subject